Literature DB >> 20205941

Factors associated with low cure rate of tuberculosis in remote poor areas of Shaanxi Province, China: a case control study.

Xianqin Ai1, Ke Men, Liujia Guo, Tianhua Zhang, Yan Zhao, Xiaolu Sun, Hongwei Zhang, Guangxue He, Marieke J van der Werf, Susan van den Hof.   

Abstract

BACKGROUND: The directly observed therapy-short course (DOTS) strategy was introduced in Shaanxi province, China to improve tuberculosis (TB) control by means of improved case detection (target: > = 70%) and treatment success rates (target: > = 85%) in new smear positive (SS+) TB patients. At a provincial level the targets were both reached in 2005. However in 30 (28%) out of 107 counties of Shaanxi province the cure rate was below 85%. This study aimed to investigate patient and treatment characteristics associated with non-cure after tuberculosis (TB) treatment in these counties.
METHODS: In this case-control study, new smear positive TB cases in 30 counties with a cure rate <85% were included. Cured patients were compared to non-cured patients using logistic regression analysis to assess determinants for non-cure.
RESULTS: Of the 659 patients included, 153 (23.2%) did not have cure as treatment outcome. Interruption of treatment was most strongly associated with non-cure (OR = 8.7, 95% CI 3.9-18.4). Other independent risk factors were co-morbidity, low education level, lack of appetite as an initial symptom of TB disease, diagnosis of TB outside of the government TB control institutes, missing sputum re-examinations during treatment, and not having a treatment observer. Twenty-six percent of patients did not have a treatment observer. The non-cure rate was better for those with a doctor (odds ratio (OR) 0.38, 95% confidence interval (CI) 0.17-0.88) as treatment observer than for those with a family member (OR 0.62, 95%CI 0.37-1.03). The main reason for interrupted treatment mentioned by patients was presence of adverse effects during treatment (46.5%).
CONCLUSIONS: Interruption of treatment was most strongly associated with non-cure. Although treatment observation by medical staff is preferred, in order to diminish the proportion of patients who do not have a treatment observer and thereby reduce the proportion of patients who interrupt treatment, we suggest making it possible for family members, after sufficient training, to be treatment observers in remote areas where it is logistically difficult to have village doctors observe treatment for all patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20205941      PMCID: PMC2838810          DOI: 10.1186/1471-2458-10-112

Source DB:  PubMed          Journal:  BMC Public Health        ISSN: 1471-2458            Impact factor:   3.295


  18 in total

1.  Drug resistance among failure and relapse cases of tuberculosis: is the standard re-treatment regimen adequate?

Authors:  H T W Quy; N T N Lan; M W Borgdorff; J Grosset; P D Linh; L B Tung; D van Soolingen; M Raviglione; N V Cô; J Broekmans
Journal:  Int J Tuberc Lung Dis       Date:  2003-07       Impact factor: 2.373

2.  Who fails to complete tuberculosis treatment? Temporal trends and risk factors for treatment interruption in a community-based directly observed therapy programme in a rural district of South Africa.

Authors:  C Connolly; G R Davies; D Wilkinson
Journal:  Int J Tuberc Lung Dis       Date:  1999-12       Impact factor: 2.373

3.  What lessons can be drawn from tuberculosis (TB) control in China in the 1990s? An analysis from a health system perspective.

Authors:  Shenglan Tang; Stephen Bertel Squire
Journal:  Health Policy       Date:  2005-04       Impact factor: 2.980

4.  Default from tuberculosis treatment programme in Sagamu, Nigeria.

Authors:  O J Daniel; O T Oladapo; O K Alausa
Journal:  Niger J Med       Date:  2006 Jan-Mar

5.  A case-control study for multidrug-resistant tuberculosis: risk factors in four European countries.

Authors:  M Casal; M Vaquero; H Rinder; E Tortoli; J Grosset; S Rüsch-Gerdes; J Gutiérrez; V Jarlier
Journal:  Microb Drug Resist       Date:  2005       Impact factor: 3.431

6.  Staff and patient attitudes to tuberculosis and compliance with treatment: an exploratory study in a district in Vietnam.

Authors:  E Johansson; V K Diwan; N D Huong; B M Ahlberg
Journal:  Tuber Lung Dis       Date:  1996-04

7.  Predictors of treatment failure among tuberculosis patients under DOTS strategy in Egypt.

Authors:  A M Morsy; H H Zaher; M H Hassan; A Shouman
Journal:  East Mediterr Health J       Date:  2003-07       Impact factor: 1.628

8.  Factors associated with tuberculosis treatment default and completion at the Effia-Nkwanta Regional Hospital in Ghana.

Authors:  Emmanuel Atsu Dodor; Godwin Yao Afenyadu
Journal:  Trans R Soc Trop Med Hyg       Date:  2005-11       Impact factor: 2.184

9.  Tuberculosis outcomes in Taipei: factors associated with treatment interruption for 2 months and death.

Authors:  C-Y Chiang; J-J Lee; M-C Yu; D A Enarson; T-P Lin; K-T Luh
Journal:  Int J Tuberc Lung Dis       Date:  2009-01       Impact factor: 2.373

10.  Mycobacterium tuberculosis Beijing genotype and risk for treatment failure and relapse, Vietnam.

Authors:  Nguyen Thi Ngoc Lan; Hoang Thi Kim Lien; Le B Tung; Martien W Borgdorff; Kristin Kremer; Dick van Soolingen
Journal:  Emerg Infect Dis       Date:  2003-12       Impact factor: 6.883

View more
  18 in total

1.  Profile and determinants of unsuccessful tuberculosis outcome in rural Nigeria: Implications for tuberculosis control.

Authors:  Kingsley N Ukwaja; Sarah N Oshi; Isaac Alobu; Daniel C Oshi
Journal:  World J Methodol       Date:  2016-03-26

2.  Role of Treatment Adherence, Doctor-Patient Trust, and Communication in Predicting Treatment Effects Among Tuberculosis Patients: Difference Between Urban and Rural Areas.

Authors:  Liang Du; Ruiheng Wu; Xu Chen; Jia Xu; Haoqiang Ji; Ling Zhou
Journal:  Patient Prefer Adherence       Date:  2020-11-24       Impact factor: 2.711

Review 3.  Patient medical costs for tuberculosis treatment and impact on adherence in China: a systematic review.

Authors:  Qian Long; Helen Smith; Tuohong Zhang; Shenglan Tang; Paul Garner
Journal:  BMC Public Health       Date:  2011-05-26       Impact factor: 3.295

4.  Treatment adherence among sputum smear-positive pulmonary tuberculosis patients in mountainous areas in China.

Authors:  Song Yao; Wen-Hui Huang; Susan van den Hof; Shu-Min Yang; Xiao-Lin Wang; Wei Chen; Xue-Hui Fang; Hai-Feng Pan
Journal:  BMC Health Serv Res       Date:  2011-12-16       Impact factor: 2.655

5.  Genotypic diversity and drug susceptibility patterns among M. tuberculosis complex isolates from South-Western Ghana.

Authors:  Dorothy Yeboah-Manu; Adwoa Asante-Poku; Thomas Bodmer; David Stucki; Kwadwo Koram; Frank Bonsu; Gerd Pluschke; Sebastien Gagneux
Journal:  PLoS One       Date:  2011-07-11       Impact factor: 3.240

Review 6.  Risk factors associated with adverse reactions to antituberculosis drugs.

Authors:  Laíse Soares Oliveira Resende; Edson Theodoro Dos Santos-Neto
Journal:  J Bras Pneumol       Date:  2015 Jan-Feb       Impact factor: 2.624

7.  Pulmonary tuberculosis incidence and risk factors in rural areas of China: a cohort study.

Authors:  Wei Chen; Wen Shu; Min Wang; Yongchun Hou; Yinyin Xia; Weiguo Xu; Liqiong Bai; Shaofa Nie; Shiming Cheng; Yihua Xu
Journal:  PLoS One       Date:  2013-03-12       Impact factor: 3.240

8.  Urban movement and alcohol intake strongly predict defaulting from tuberculosis treatment: an operational study.

Authors:  Ibrahim Sendagire; Maarten Schim Van der Loeff; Andrew Kambugu; Joseph Konde-Lule; Frank Cobelens
Journal:  PLoS One       Date:  2012-05-02       Impact factor: 3.240

9.  Patterns of treatment interruption among patients with multidrug-resistant TB (MDR TB) and association with interim and final treatment outcomes.

Authors:  Laura Jean Podewils; Maria Tarcela S Gler; Maria Imelda Quelapio; Michael P Chen
Journal:  PLoS One       Date:  2013-07-29       Impact factor: 3.240

10.  Insight to the Epidemiology and Risk Factors of Extrapulmonary Tuberculosis in Tianjin, China during 2006-2011.

Authors:  Xiaoqing Wang; Zhenhua Yang; Yanyong Fu; Guoqin Zhang; Xu Wang; Yuhua Zhang; Xiexiu Wang
Journal:  PLoS One       Date:  2014-12-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.